Efficacy and Safety of Eplerenone for Treating Chronic Kidney Disease: A Meta-Analysis.
Journal
International journal of hypertension
ISSN: 2090-0384
Titre abrégé: Int J Hypertens
Pays: United States
ID NLM: 101538881
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
12
2022
revised:
08
02
2023
accepted:
01
03
2023
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
In recent years, a large amount of clinical evidence and animal experiments have demonstrated the unique advantages of mineralocorticoid receptor antagonists (MRA) for treating chronic kidney disease (CKD). Accordingly, the present study aimed to systematically assess the second-generation selective MRAs eplerenone's safety and effectiveness for treating CKD. Four databases (PubMed, The Cochrane Library, Embase, and Web of Science) were searched for randomized controlled trials (RCT) correlated with eplerenone for treating CKD up to September 21, 2022. By complying with the inclusion and exclusion criteria, literature screening, and data extraction were conducted. A total of 19 randomized controlled articles involving 4501 cases were covered. As suggested from the meta-analysis, significant differences were reported with the 24-h urine protein (MD = -42.23, 95% confidence interval [CI] = -76.72 to -7.73, Eplerenone has beneficial effects on CKD by reducing urinary protein and the systolic blood pressure, but it also elevates the risk of hyperkalemia.
Sections du résumé
Background
UNASSIGNED
In recent years, a large amount of clinical evidence and animal experiments have demonstrated the unique advantages of mineralocorticoid receptor antagonists (MRA) for treating chronic kidney disease (CKD).
Aims
UNASSIGNED
Accordingly, the present study aimed to systematically assess the second-generation selective MRAs eplerenone's safety and effectiveness for treating CKD.
Methods
UNASSIGNED
Four databases (PubMed, The Cochrane Library, Embase, and Web of Science) were searched for randomized controlled trials (RCT) correlated with eplerenone for treating CKD up to September 21, 2022. By complying with the inclusion and exclusion criteria, literature screening, and data extraction were conducted.
Results
UNASSIGNED
A total of 19 randomized controlled articles involving 4501 cases were covered. As suggested from the meta-analysis, significant differences were reported with the 24-h urine protein (MD = -42.23, 95% confidence interval [CI] = -76.72 to -7.73,
Conclusions
UNASSIGNED
Eplerenone has beneficial effects on CKD by reducing urinary protein and the systolic blood pressure, but it also elevates the risk of hyperkalemia.
Identifiants
pubmed: 36938116
doi: 10.1155/2023/6683987
pmc: PMC10019978
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6683987Informations de copyright
Copyright © 2023 Honglei Hu et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest in this manuscript.
Références
Circ J. 2016 Apr 25;80(5):1113-22
pubmed: 27074824
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Int J Med Sci. 2014 Jun 21;11(9):897-904
pubmed: 25013370
PLoS One. 2022 Mar 24;17(3):e0265642
pubmed: 35324976
Int J Clin Pract. 2019 Aug 29;:e13413
pubmed: 31464019
Pharmaceuticals (Basel). 2021 Jun 11;14(6):
pubmed: 34208285
Circulation. 2003 Oct 14;108(15):1831-8
pubmed: 14517164
Clin J Am Soc Nephrol. 2006 Sep;1(5):940-51
pubmed: 17699311
Diabetes Metab. 2021 Jul;47(4):101190
pubmed: 32919068
PLoS One. 2011;6(11):e26904
pubmed: 22073219
PLoS One. 2013 May 21;8(5):e64549
pubmed: 23704994
Eur J Heart Fail. 2019 Mar;21(3):345-351
pubmed: 30768732
Mayo Clin Proc Innov Qual Outcomes. 2022 Oct 15;6(6):536-551
pubmed: 36277502
Pol Arch Med Wewn. 2013;123(5):221-7
pubmed: 23615633
Drug Dev Res. 2021 May;82(3):341-363
pubmed: 33179798
Drug Des Devel Ther. 2018 Aug 24;12:2611-2616
pubmed: 30197501
Adv Exp Med Biol. 2019;1165:3-15
pubmed: 31399958
J Am Soc Nephrol. 2011 Jul;22(7):1353-64
pubmed: 21719791
Diabetes Ther. 2021 Sep;12(9):2485-2498
pubmed: 34351585
PLoS Med. 2020 Dec 11;17(12):e1003470
pubmed: 33306688
Kidney Int. 2004 Jun;65(6):2309-20
pubmed: 15149345
J Clin Hypertens (Greenwich). 2016 Dec;18(12):1250-1257
pubmed: 27296360
Sci Rep. 2020 Oct 6;10(1):16626
pubmed: 33024237
J Clin Endocrinol Metab. 2007 Jul;92(7):2552-8
pubmed: 17488800
Lancet Diabetes Endocrinol. 2014 Dec;2(12):944-53
pubmed: 25466242
Clin Exp Nephrol. 2015 Apr;19(2):247-53
pubmed: 24821289
Cardiorenal Med. 2020;10(6):392-401
pubmed: 32998143
Kidney Blood Press Res. 2012;36(1):335-43
pubmed: 23235363
Diabetes Obes Metab. 2020 Apr;22 Suppl 1:3-15
pubmed: 32267079
J Clin Hypertens (Greenwich). 2017 Oct;19(10):990-998
pubmed: 28849629
Sci Rep. 2021 Mar 12;11(1):5846
pubmed: 33712668
Clin Exp Hypertens. 2016;38(7):565-570
pubmed: 27651039
Am J Cardiol. 2004 Apr 15;93(8):990-6
pubmed: 15081441
Int J Hypertens. 2016;2016:5091951
pubmed: 27843645
J Diabetes Investig. 2017 Jul;8(4):609-618
pubmed: 28107779
Res Vet Sci. 2020 Dec;133:150-156
pubmed: 32992126
Hypertension. 2003 May;41(5):1021-6
pubmed: 12682082
J Am Coll Cardiol. 2013 Oct 22;62(17):1585-93
pubmed: 23810881
J Clin Hypertens (Greenwich). 2017 Jul;19(7):669-676
pubmed: 28211216